JP7009012B2 - N-レチノイルシステイン酸アルキルエステルの製造方法 - Google Patents
N-レチノイルシステイン酸アルキルエステルの製造方法 Download PDFInfo
- Publication number
- JP7009012B2 JP7009012B2 JP2018530592A JP2018530592A JP7009012B2 JP 7009012 B2 JP7009012 B2 JP 7009012B2 JP 2018530592 A JP2018530592 A JP 2018530592A JP 2018530592 A JP2018530592 A JP 2018530592A JP 7009012 B2 JP7009012 B2 JP 7009012B2
- Authority
- JP
- Japan
- Prior art keywords
- acid
- alkyl ester
- phase
- carbon atoms
- retinoyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- XVOYSCVBGLVSOL-UHFFFAOYSA-N L-cysteine sulfonic acid Natural products OC(=O)C(N)CS(O)(=O)=O XVOYSCVBGLVSOL-UHFFFAOYSA-N 0.000 title claims description 16
- 238000004519 manufacturing process Methods 0.000 title claims description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 60
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical group CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 36
- 125000004432 carbon atom Chemical group C* 0.000 claims description 35
- 238000000034 method Methods 0.000 claims description 34
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 32
- 239000007791 liquid phase Substances 0.000 claims description 30
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 26
- 239000000203 mixture Substances 0.000 claims description 25
- 239000011541 reaction mixture Substances 0.000 claims description 23
- 239000002253 acid Substances 0.000 claims description 20
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 20
- 229960001727 tretinoin Drugs 0.000 claims description 20
- 229930002330 retinoic acid Natural products 0.000 claims description 19
- -1 aliphatic alcohols Chemical class 0.000 claims description 17
- 125000005907 alkyl ester group Chemical group 0.000 claims description 15
- 239000012071 phase Substances 0.000 claims description 14
- 125000000217 alkyl group Chemical group 0.000 claims description 13
- 150000001412 amines Chemical class 0.000 claims description 13
- 238000006243 chemical reaction Methods 0.000 claims description 13
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 13
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 12
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 11
- 150000003458 sulfonic acid derivatives Chemical class 0.000 claims description 11
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 11
- 230000001590 oxidative effect Effects 0.000 claims description 9
- 239000000010 aprotic solvent Substances 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical group CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 claims description 5
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 claims description 5
- SHGAZHPCJJPHSC-XFYACQKRSA-N isotretinoin Chemical compound OC(=O)/C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-XFYACQKRSA-N 0.000 claims description 5
- 229960005280 isotretinoin Drugs 0.000 claims description 5
- 229960003080 taurine Drugs 0.000 claims description 5
- ADVPTQAUNPRNPO-REOHCLBHSA-N 3-sulfino-L-alanine Chemical compound OC(=O)[C@@H](N)C[S@@](O)=O ADVPTQAUNPRNPO-REOHCLBHSA-N 0.000 claims description 4
- 125000001931 aliphatic group Chemical group 0.000 claims description 4
- ADVPTQAUNPRNPO-UHFFFAOYSA-N alpha-amino-beta-sulfino-propionic acid Natural products OC(=O)C(N)CS(O)=O ADVPTQAUNPRNPO-UHFFFAOYSA-N 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 3
- 235000018417 cysteine Nutrition 0.000 claims description 3
- PDNJLMZEGXHSCU-UHFFFAOYSA-N homocysteine sulfinic acid Chemical compound OC(=O)C(N)CCS(O)=O PDNJLMZEGXHSCU-UHFFFAOYSA-N 0.000 claims description 2
- 238000004237 preparative chromatography Methods 0.000 claims description 2
- 125000005270 trialkylamine group Chemical group 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 238000005191 phase separation Methods 0.000 claims 1
- 239000000243 solution Substances 0.000 description 21
- 239000000047 product Substances 0.000 description 19
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 15
- 150000001298 alcohols Chemical class 0.000 description 13
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 239000003960 organic solvent Substances 0.000 description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 239000008346 aqueous phase Substances 0.000 description 9
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 8
- 239000004593 Epoxy Substances 0.000 description 7
- 238000001704 evaporation Methods 0.000 description 7
- 230000008020 evaporation Effects 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 239000000376 reactant Substances 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 6
- 239000012043 crude product Substances 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 239000012264 purified product Substances 0.000 description 5
- 239000000377 silicon dioxide Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 230000005526 G1 to G0 transition Effects 0.000 description 4
- 150000004292 cyclic ethers Chemical class 0.000 description 4
- 150000002170 ethers Chemical class 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 4
- 125000001444 retinoyl group Chemical group O=C([*])/C([H])=C(C([H])([H])[H])/C([H])=C([H])/C([H])=C(C([H])([H])[H])/C([H])=C([H])/C1=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])([H])C1(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- ATJKKHLWQIDEMZ-VKHMYHEASA-N (2r)-2-amino-3-methoxy-3-oxopropane-1-sulfonic acid Chemical compound COC(=O)[C@@H](N)CS(O)(=O)=O ATJKKHLWQIDEMZ-VKHMYHEASA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 150000008064 anhydrides Chemical class 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 238000001819 mass spectrum Methods 0.000 description 3
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 3
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 3
- 239000012258 stirred mixture Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- KEEHJLBAOLGBJZ-WEDZBJJJSA-N 5,6-epoxyretinoic acid Chemical compound C1CCC(C)(C)C2(/C=C/C(/C)=C/C=C/C(/C)=C/C(O)=O)C1(C)O2 KEEHJLBAOLGBJZ-WEDZBJJJSA-N 0.000 description 2
- SHGAZHPCJJPHSC-ZVCIMWCZSA-N 9-cis-retinoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 2
- 229960001445 alitretinoin Drugs 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 238000013375 chromatographic separation Methods 0.000 description 2
- 238000011097 chromatography purification Methods 0.000 description 2
- 150000002191 fatty alcohols Chemical class 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 150000003460 sulfonic acids Chemical class 0.000 description 2
- 0 CC(C)(*)CC(C)(C)C(C(O*)=O)N Chemical compound CC(C)(*)CC(C)(C)C(C(O*)=O)N 0.000 description 1
- XOBKSJJDNFUZPF-UHFFFAOYSA-N Methoxyethane Chemical compound CCOC XOBKSJJDNFUZPF-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 238000005377 adsorption chromatography Methods 0.000 description 1
- GGCUJPCCTQNTJF-FRCNGJHJSA-N all-trans-4-oxoretinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C(=O)CCC1(C)C GGCUJPCCTQNTJF-FRCNGJHJSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- NRDQFWXVTPZZAZ-UHFFFAOYSA-N butyl carbonochloridate Chemical compound CCCCOC(Cl)=O NRDQFWXVTPZZAZ-UHFFFAOYSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000011210 chromatographic step Methods 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- POLCUAVZOMRGSN-UHFFFAOYSA-N dipropyl ether Chemical compound CCCOCCC POLCUAVZOMRGSN-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229940087646 methanolamine Drugs 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000004305 normal phase HPLC Methods 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 238000012805 post-processing Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003586 protic polar solvent Substances 0.000 description 1
- 150000004508 retinoic acid derivatives Chemical class 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- GJPYYNMJTJNYTO-UHFFFAOYSA-J sodium aluminium sulfate Chemical compound [Na+].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GJPYYNMJTJNYTO-UHFFFAOYSA-J 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- BUUPQKDIAURBJP-UHFFFAOYSA-N sulfinic acid Chemical compound OS=O BUUPQKDIAURBJP-UHFFFAOYSA-N 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/04—Compounds containing oxirane rings containing only hydrogen and carbon atoms in addition to the ring oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
- C07C403/22—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
- C07C403/20—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by carboxyl groups or halides, anhydrides, or (thio)esters thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D301/00—Preparation of oxiranes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D301/00—Preparation of oxiranes
- C07D301/32—Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/38—Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D303/46—Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals by amide or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Furan Compounds (AREA)
- Epoxy Compounds (AREA)
Description
nは、0~2であり、
Zは、2又は3であり、
Aは、結合又は酸素原子であり、
X及びYは、H若しくは-OH又は合わせてOであり、
炭素原子3と4との間は二重結合であり、但しX及びYはHであり、
炭素原子9と10、11と12、13と14の間の二重結合の構成はE-又はZ-であってもよく、
R1及びR2は、H、1~4個の炭素原子を含む低級アルキル、又は-COOH若しくはその薬学的に許容される塩、又はCOOR3であり、ここでR3は1~4個の炭素原子を含むアルキル基であり、
Mは薬学的に許容されるカチオンである。
Claims (13)
- N-レチノイルアミノアルカンスルホン酸誘導体の製造方法であって、
i)システイン酸及びそのアルキルエステル、システインスルフィン酸及びそのアルキルエステル、ホモシステイン酸及びそのアルキルエステル、ホモシステインスルフィン酸及びそのアルキルエステル、タウリン及び下記式で表されるタウリンの誘導体からなる群から選択されるアミノアルカンスルホン酸、1~4個の炭素原子を含む脂肪族アルコールから選択されるアルコール、並びにトリアルキルアミンから選択される第1の塩基を含む第1の溶液、
(式中、nは0、1又は2であり、R 5 は水素又はメチル基である。)
ii)レチノイン酸、クロロホルメート、非プロトン性溶媒、及び第2の塩基を含む第2の溶液、
を提供する工程と、
前記第1及び第2の溶液を任意の順序で反応容器に加えることによって、1相である液相を含む反応混合物を形成する工程と、
前記反応混合物を混合する工程と、
を含み、
前記レチノイン酸、アミノアルカンスルホン酸、及びクロロホルメートは、全て可溶性で及び前記液相中に存在し、並びに
前記N-レチノイルアミノアルカンスルホン酸誘導体が、酸化化合物を実質的に含まないことを特徴とする条件下で前記液相中に形成される、方法。 - 前記N-レチノイルアミノアルカンスルホン酸誘導体が、N-(13-シス-レチノイル)-システイン酸アルキルエステル及びN-(全トランス-レチノイル)-システイン酸アルキルエステルから選択され、
前記レチノイン酸が、13-シス-レチノイン酸又は全トランスレチノイン酸から選択され、並びに
前記アミノアルカンスルホン酸が、システイン酸アルキルエステルから選択される、請求項1に記載の方法。 - 前記アルコールが、メタノール若しくはエタノール又はそれらの混合物からなる群から選択される、請求項1又は2に記載の方法。
- 前記非プロトン性溶媒がテトラヒドロフランである、請求項1~3のいずれか1項に記載の方法。
- 前記クロロホルメートが、2~6個の炭素原子を含む脂肪族基を含む、請求項1~4のいずれか1項に記載の方法。
- 前記クロロホルメートがイソブチルクロロホルメートである、請求項1~5のいずれか1項に記載の方法。
- 前記第2の塩基がアミンである、請求項1~6のいずれか1項に記載の方法。
- 前記アミンが、トリアルキルアミンである、請求項7に記載の方法。
- 前記アミンが、トリエチルアミンである、請求項7に記載の方法。
- 前記単相が、相分離を伴わない1相である、請求項1~9のいずれか1項に記載の方法。
- 前記N-レチノイルアミノアルカンスルホン酸誘導体が分取クロマトグラフィーを用いて精製される、請求項1~10のいずれか1項に記載の方法。
- 前記N-レチノイルアミノアルカンスルホン酸誘導体のアルキル基及び前記アミノアルカンスルホン酸のアルキルが1~3個の炭素原子を含む、請求項1~11のいずれか1項に記載の方法。
- 前記アルキル基がメチルである、請求項12に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE1551615 | 2015-12-09 | ||
SE1551615-6 | 2015-12-09 | ||
PCT/SE2016/051238 WO2017099662A1 (en) | 2015-12-09 | 2016-12-09 | Method for producing n-retinoylcysteic acid alkyl ester |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2019504005A JP2019504005A (ja) | 2019-02-14 |
JP7009012B2 true JP7009012B2 (ja) | 2022-01-25 |
Family
ID=59013796
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018530592A Active JP7009012B2 (ja) | 2015-12-09 | 2016-12-09 | N-レチノイルシステイン酸アルキルエステルの製造方法 |
Country Status (21)
Country | Link |
---|---|
US (2) | US10138204B2 (ja) |
EP (1) | EP3386947B1 (ja) |
JP (1) | JP7009012B2 (ja) |
KR (1) | KR20180091851A (ja) |
CN (2) | CN116444463A (ja) |
AU (1) | AU2016365535B2 (ja) |
BR (1) | BR112018011414B1 (ja) |
CA (1) | CA3007624C (ja) |
DK (1) | DK3386947T3 (ja) |
EA (1) | EA037846B1 (ja) |
ES (1) | ES2881882T3 (ja) |
HK (1) | HK1258219A1 (ja) |
LT (1) | LT3386947T (ja) |
MX (1) | MX2018006894A (ja) |
MY (1) | MY184709A (ja) |
NZ (1) | NZ743639A (ja) |
SG (1) | SG11201804826TA (ja) |
SI (1) | SI3386947T1 (ja) |
UA (1) | UA124338C2 (ja) |
WO (1) | WO2017099662A1 (ja) |
ZA (1) | ZA201804250B (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110218168B (zh) * | 2018-03-02 | 2022-09-20 | 上海现代药物制剂工程研究中心有限公司 | 一种n-(全反式-视黄酰基)-l-半胱磺酸甲酯的钠盐的制备方法 |
CN112239418B (zh) * | 2019-07-18 | 2023-07-07 | 上海现代药物制剂工程研究中心有限公司 | 视黄醇类化合物及其钠盐的制备方法 |
US11072575B1 (en) * | 2020-09-19 | 2021-07-27 | Xi'an Taikomed Pharmaceutical Technology Co., Ltd. | Method of preparing a cinnamyl alcohol retinoic acid ester with antioxidant and antibacterial activities |
US11401239B1 (en) | 2020-10-13 | 2022-08-02 | Fxi Inc. Limited | Process for converting disulfides to conversion products and process for producing cysteic acid |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030050343A1 (en) | 2001-05-15 | 2003-03-13 | Oleg Strelchenok | Novel potentiating compounds |
US20040048923A1 (en) | 2002-07-23 | 2004-03-11 | Oleg Strelchenok | Therapeutic compounds |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3002545A1 (de) * | 1980-01-25 | 1981-07-30 | Basf Ag, 6700 Ludwigshafen | 5-amino-tetrazol-derivate von retinsaeuren, ihre herstellung und diese enthaltende pharmazeutische zubereitungen |
AU2002347747A1 (en) * | 2002-07-23 | 2004-02-09 | Ardenia Investments Ltd. | Retinol derivatives, their use in the treatment of cancer and for potentiating the efficacy of other cytotoxic agents |
US7321064B1 (en) * | 2007-03-08 | 2008-01-22 | Cedarburg Pharmaceuticals, Inc. | Preparation of amides of retinoic acid via mixed anhydride and mixed carbonate intermediates |
-
2016
- 2016-12-09 AU AU2016365535A patent/AU2016365535B2/en active Active
- 2016-12-09 CA CA3007624A patent/CA3007624C/en active Active
- 2016-12-09 MX MX2018006894A patent/MX2018006894A/es unknown
- 2016-12-09 MY MYPI2018702173A patent/MY184709A/en unknown
- 2016-12-09 LT LTEP16873468.9T patent/LT3386947T/lt unknown
- 2016-12-09 ES ES16873468T patent/ES2881882T3/es active Active
- 2016-12-09 SG SG11201804826TA patent/SG11201804826TA/en unknown
- 2016-12-09 SI SI201631233T patent/SI3386947T1/sl unknown
- 2016-12-09 EA EA201891259A patent/EA037846B1/ru unknown
- 2016-12-09 JP JP2018530592A patent/JP7009012B2/ja active Active
- 2016-12-09 CN CN202310373566.8A patent/CN116444463A/zh active Pending
- 2016-12-09 EP EP16873468.9A patent/EP3386947B1/en active Active
- 2016-12-09 CN CN201680071797.1A patent/CN108473421A/zh active Pending
- 2016-12-09 BR BR112018011414-6A patent/BR112018011414B1/pt active IP Right Grant
- 2016-12-09 DK DK16873468.9T patent/DK3386947T3/da active
- 2016-12-09 WO PCT/SE2016/051238 patent/WO2017099662A1/en active Application Filing
- 2016-12-09 KR KR1020187017826A patent/KR20180091851A/ko active Pending
- 2016-12-09 UA UAA201807009A patent/UA124338C2/uk unknown
- 2016-12-09 NZ NZ743639A patent/NZ743639A/en unknown
-
2018
- 2018-06-08 US US16/003,209 patent/US10138204B2/en active Active
- 2018-06-25 ZA ZA2018/04250A patent/ZA201804250B/en unknown
- 2018-10-31 US US16/176,215 patent/US10322996B2/en active Active
-
2019
- 2019-01-14 HK HK19100577.0A patent/HK1258219A1/zh unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030050343A1 (en) | 2001-05-15 | 2003-03-13 | Oleg Strelchenok | Novel potentiating compounds |
US20040048923A1 (en) | 2002-07-23 | 2004-03-11 | Oleg Strelchenok | Therapeutic compounds |
Also Published As
Publication number | Publication date |
---|---|
EP3386947B1 (en) | 2021-05-19 |
EA037846B1 (ru) | 2021-05-27 |
AU2016365535B2 (en) | 2020-07-23 |
AU2016365535A1 (en) | 2018-07-12 |
US10322996B2 (en) | 2019-06-18 |
CN108473421A (zh) | 2018-08-31 |
LT3386947T (lt) | 2021-09-10 |
CA3007624C (en) | 2024-04-09 |
MX2018006894A (es) | 2018-11-09 |
US20190127322A1 (en) | 2019-05-02 |
HK1258219A1 (zh) | 2019-11-08 |
CN116444463A (zh) | 2023-07-18 |
ZA201804250B (en) | 2019-04-24 |
ES2881882T3 (es) | 2021-11-30 |
MY184709A (en) | 2021-04-19 |
KR20180091851A (ko) | 2018-08-16 |
SI3386947T1 (sl) | 2021-11-30 |
NZ743639A (en) | 2022-07-01 |
CA3007624A1 (en) | 2017-06-15 |
DK3386947T3 (da) | 2021-08-09 |
UA124338C2 (uk) | 2021-09-01 |
WO2017099662A1 (en) | 2017-06-15 |
JP2019504005A (ja) | 2019-02-14 |
EP3386947A1 (en) | 2018-10-17 |
BR112018011414A2 (pt) | 2018-11-27 |
EA201891259A1 (ru) | 2019-01-31 |
US10138204B2 (en) | 2018-11-27 |
US20180290973A1 (en) | 2018-10-11 |
SG11201804826TA (en) | 2018-07-30 |
BR112018011414B1 (pt) | 2022-09-20 |
EP3386947A4 (en) | 2019-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7009012B2 (ja) | N-レチノイルシステイン酸アルキルエステルの製造方法 | |
JP6659563B2 (ja) | 高純度プロスタグランジンの新規製造方法 | |
DK2534130T3 (en) | METHOD OF PRODUCING astaxanthin-DIMETHYLDISUCCINAT | |
CN104829465A (zh) | 一种4-异丙氨基-1-丁醇的制备方法 | |
JP2018127479A (ja) | 2−((5z,8z,11z,14z,17z)−イコサ−5,8,11,14,17−ペンタエニルオキシ)ブタン酸を調製する方法 | |
CN112574056B (zh) | 一种α,α-二氟-γ-羟基乙酰胺衍生物的合成方法 | |
CN104530112A (zh) | 依维莫司中间体及其乙基化杂质的制备方法 | |
KR20090101234A (ko) | 트리스(퍼플루오로알칸설포닐)메티드산염의 제조방법 | |
CN101468936A (zh) | 醇羟基氟代衍生物的合成方法 | |
US8492579B2 (en) | Method for producing astaxanthin dimethyldisuccinate | |
KR20230154213A (ko) | 알킬-4-옥소테트라히드로푸란-2-카르복실레이트의 제조 방법 | |
WO2023007712A1 (ja) | (r,s)-ニコチンの製造方法 | |
JP2024045205A (ja) | 2-ヒドロキシ-2-(パーフルオロアルキル)マロン酸エステル誘導体の製造方法、並びに2-(トリメチルシリルオキシ)-2-(パーフルオロアルキル)マロン酸エステル誘導体及び5-ヒドロキシ-5-(パーフルオロアルキル)ピリミジン-2,4,6(1h,3h,5h)-トリオンとそれらの製造方法 | |
WO2020148780A1 (en) | Process for preparation of 4,4,4- trifluorobut-2-en-1-ol and intermediate thereof | |
JP4825969B2 (ja) | 第3級アルコールの製造方法 | |
CN108329255A (zh) | 一种六氢咔唑酮衍生物的合成方法 | |
FR2935976A1 (fr) | Voie courte de synthese du 1,6:2,3-dianhydro-b-d- mannopyranose. | |
WO2018066146A1 (ja) | フッ素化化合物の製造方法 | |
WO2014142064A1 (ja) | 3,3,3-トリフルオロ-2,2-ジアルキルプロピオン酸エステルの製造方法 | |
CN109153660A (zh) | 用于制备具有增强稳定性的依前列醇钠的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A529 | Written submission of copy of amendment under article 34 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A529 Effective date: 20180627 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20190917 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20191106 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200908 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201208 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210309 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20210428 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210607 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20210428 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20211214 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220106 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7009012 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |